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Despite many efforts to develop hormone therapy and 
chemotherapy, no effective strategy to suppress prostate cancer 
metastasis has been established because the metastasis is not 
well understood. I here investigate a role of CBP/p300-
interacting transactivator with E/D-rich carboxy-terminal 
domain-2 (CITED2) in prostate cancer metastasis. CITED2 is 
highly expressed in metastatic prostate cancer, and its 
expression is correlated with poor survival. The CITED2 gene is 
highly activated by ETS-related gene that is overexpressed due 
to chromosomal translocation. CITED2 acts as a molecular 
chaperone to guide PRMT5 and p300 to nucleolin, thereby 
activating nucleolin. Informatics and experimental data suggest 
that the CITED2-nucleolin axis is involved in prostate cancer 
metastasis. This axis stimulates cell migration through the 
epithelial–mesenchymal transition and promotes cancer 
metastasis in a xenograft mouse model. Our results suggest that 
CITED2 plays a metastasis-promoting role in prostate cancer 
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INTRODUCTION
Prostate cancer is the most frequently diagnosed cancer and 
the second leading cause of cancer-related death among males. 
Despite many efforts to develop hormone therapy and 
chemotherapy, the prognoses of patients with advanced prostate 
cancer remains poor, because these treatments cannot control 
cancer metastasis (1, 2). One of the most distinct features of 
prostate cancer is that more than half of the patients display gene 
fusion between androgen-responsive gene TMPRSS2 and ETS 
transcription factor genes such as ERG and ETV1 (3). 
TMPRSS2-ERG fusion is reported to promote cancer 
progression (4, 5), but the downstream mechanism is not clearly 
known.
CBP/p300-interacting transactivator with E/D-rich 
carboxy-terminal domain 2 (CITED2, also known as MRG1 and 
p35srj) is a transcriptional coregulator together with the 
transcriptional coactivator p300/CBP. Depending on its target 
gene, it functions as a positive or negative regulator of gene 
expression. For example, CITED2 acts as a coactivator of AP-2 
transcription factors by recruiting p300/CBP to AP-2 target 
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genes (6). In contrast, CITED2 inhibits hypoxia-induced gene 
expression by preventing p300/CBP recruitment to the hypoxia-
inducible factor 1a (HIF-1 a) (7). CITED2 interacts with other 
components besides the aforementioned proteins. CITED2 
expression is induced by hypoxia, lipopolysaccharides, growth 
factors, and proinflammatory cytokines (8). CITED2 also plays 
essential roles in embryonic stem cell differentiation (9) and 
development of diverse organs, including liver (10), lung (11), 
heart (12), and lens (13). Furthermore, adult hematopoietic stem 
cell (HSC) functions are maintained by CITED2 via lnk4a/Arf and 
Trp53 (14), and acute myeloid leukemia critically requires 
CITED2 expression (15). However, only a few investigations 
have been conducted on the role of CITED2 in tumor 
development during the last decade. CITED2 was reported to 
promote tumorigenesis of Rat1 cells (8) and growth of lung 
cancer cells (16). However, CITED2 inhibited proliferation of 
colon cancer cells (17), and low expression of CITED2 was 
associated with a poor prognosis in breast cancer (18). In 
particular, CITED2 is suspected to be extensively involved in 
prostate cancer, since its expression is induced by an ETS family 
member ELK1 (19), which has been reported to recruit AR to 
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activate growth signaling in prostate cancer cells (20). In this 
study, I performed co-immunoprecipitation and shotgun 
proteomics to discover a CITED2-interacting protein, and 
identified nucleolin. Nucleolin is an RNA-binding nulceolar 
protein, which has been reported to stimulate cancer progression 
and metastasis (21-23), although the exact underlying 
mechanism has not been determined. 
Nucleolin is widely known to regulate rRNA transcription of 
the engrafting complex of pre-ribosomes. Nucleolin binds to 
non-transcribed spacers of rDNA transcription initiation sites or 
interacts with histone-1 to induce de-condensation of chromatin 
structures (24, 25). Nucleolin also forms the pre-rRNA 
processing complex by recruiting U3 snoRNP (26, 27). Moreover, 
Nucleolin promotes translation of target mRNAs by binding to 
their G-rich mRNA coding regions to facilitate polysome 
formation on transcripts (28). Nucleolin consists of three 
functional domains: the N-terminal domain composed of highly 
acidic regions intermixed with basic regions, the RNA-binding 
domain, and the glycine- and arginine-rich domain. Nucleolin is 
post-translationally modified by casein kinase 2 and p43cdc2, 
which phosphorylate nucleolin at serine residues within the 
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acidic regions (29) and at threonine residues within the basic 
regions, respectively (30). These phosphorylation events of 
nucleolin are regulated throughout the cell cycle. Notably, P300-
mediated acetylation (31) and PRMT5-mediated methylation 
(32) of nucleolin have also been reported, but no studies have 
been conducted on the oncogenic functional changes induced by 
these post-translational modifications of nucleolin.
In the present study, I found that CITED2 was highly 
expressed in metastatic prostate cancer because of TMPRSS2-
ERG gene fusion, which promoted metastasis by activating 
nucleolin at the post-translational level. I also propose that the 
CITED2-nucleolin signaling pathway is a potential target for 




Antibodies against CITED2, PRMT5, β-tubulin, WDR77, 
RioK1, p300, β-CTN, Vimentin, TWIST, Snail, N-Cad and 
ZEB1 were purchased from Santa Cruz Biotechnology (Santa 
Cruz, CA); anti-nucleolin, anti-dimethyl-arginine and anti-
acetyl-lysine from Upstate Biotechnology (Lake Placid, NY); 
anti-p-AKT, anti-AKT and anti-E-cadherin from Cell 
Signaling (Danvers, MA); anti-FLAG, anti-MYC and anti-HA 
from Sigma–Aldrich (St. Louis, MO); anti-ERG and anti-a-SMA 
from Abcam (Cambridge, MA). MK2206 was purchased from 
Selleckchem. Human recombinant proteins of CITED2, PRMT5, 
P300, nucleolin were purchased from Origene. Fetal bovine 
serum (FBS), dithiothreitol (DTT), G418 disulfate salts (G418), 
EPZ015666, Leptomycin B, Bay-11-7082, LY294002, 
Cycloheximide, Wortmannin and others were obtained from 
Sigma–Aldrich.
siRNAs and plasmids
The nucleotide sequences (5’ to 3’) of siRNAs are; 
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UUAUGUCCUUGGUGAUAGATT for CITED2 (NM_006079), 
AGACUAUAGAGGUGGAAAGAAAGC for nucleolin
(NM_005381), AUGAUGUUGAUAAAGCCU, 
CGUCCUCAGUUAGAUCCU and CCACGGUUAAUGCAUGCU for 
ERG #1~3 (NM_001136154), GGACUGGAAUACGCUAAU for 
PRMT5 (NM_001039619), GACAAAACCGUGGAAGUA for 
p300 (NM_001429), CCUCACAGCCCUGAAGUACUCUUTC for 
AKT (NM_005163) and AUGAACGUGAAUUGCUCAA for non-
targeting control. The cDNAs of CITED2, nucleolin, luciferase, 
luciferase-CITED2 were cloned by reverse transcription and 
PCR using Pfu DNA polymerase, and the cDNAs were inserted 
into pcDNA, Myc-tagged, FLAG-tagged, HA-tagged, or 
FLAG/streptavidin-binding protein (SBP)-tagged vectors by 
blunt-end ligation. TRC lentiviral shRNA targeting CITED2 or 
nucleolin were purchased from Dharmacon (Lafayette, CO).
Cell lines and cell culture
HEK293T (human embryonic kidney) and human prostate 
cancer (PC3, DU145, VCaP, LNCaP, C42B, and 22RV1) cell lines 
were obtained from the American Type Culture Collection 
(Manassas, VA). Mycoplasma contamination was routinely 
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tested when cell growth or shape was changed. The cell lines 
were cultured in RPMI1640 or DMEM supplemented with 10% 
heat-inactivated FBS in a 5% CO2 humidified atmosphere at 
37°C. Luciferase-expressing and luciferase/CITED2-
coexpressing PC3 stable cell lines were established from five 
G418-resistant clones per cell line. The expression of luciferase 
has been confirmed with luciferase assay. 
Immunoblotting and immunoprecipitation
Cell lysates were separated on SDS-polyacrylamide gels, and 
transferred to Immobilon-P membranes (Millipore; Bedford, 
MA). Membranes were blocked with a Tris/saline solution 
containing 5% skim milk and 0.1% Tween-20 for 1 hour, and 
incubated with a primary antibody overnight at 4°C. Membranes 
were incubated with a horseradish peroxidase–conjugated 
secondary antibody for 1 hour, and visualized using the ECL kit 
(Thermo; Rockford, IL). To analyze protein interactions, cell 
lysates were incubated with anti-CITED2, anti-Flag or anti-
Ac-K or dimethyl-R antibody for 4 hours at 4°C, and the 
immune complexes were precipitated with protein A/G beads 
(Santa Cruz, CA). Precipitated proteins were eluted in a 
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denaturing 2xSDS sample buffer, loaded on SDS-PAGE, and 
immunoblotted.
Immunohistochemistry (IHC) of Human Prostate Cancer Tissue 
array
Human prostate cancer tissue arrays were purchased from 
SuperBioChips Lab (Seoul, South Korea). Tumor staging was 
defined according to the AJCC cancer staging manual (7th edition) 
(33). The array slides were dried for 1 hour in an oven at 60°C, 
dewaxed, and autoclaved in an antigen retrieval solution. Tissue 
sections were treated with 3% H2O2, and then incubated with a 
primary antibody (against CITED2, ERG or p-AKT) overnight 
at 4°C, and with a biotinylated secondary antibody for 1 hour at 
room temperature. The immune complexes were visualized using 
the Vectastatin ABC kit (Vector Laboratories, Burlingame, CA), 
and tissue slides were counterstained with hematoxylin for 10 
min. The immune-stained cells were counted at 4 high-power 
fields for each tissue.
Immunofluorescence
Cells grown on cover slides were fixed with methanol for 30 
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min, permeabilized with 0.1% Triton X-100 for 10 min, blocked 
by 3% BSA for 2 h, and then incubated with a primary antibody 
in the dark overnight at 4°C. The slides were incubated with 
Alexa Flour® 488 IgG anti-mouse/rabbit (green, 1:200), Alexa 
Flour® 568 IgG anti-goat (red, 1:200), Alexa Flour® 647 IgG 
anti-mouse (purple, 1:200), or Alexa Flour® 633 phalloidin (F-
actin) solution in the dark for 1 h. Then, nuclei were stained with 
4’,6-diamidino-2-phenylindole (DAPI) for 10 min. 
Fluorescence images were photographed using confocal 
microscopy.
Orthotopic Xenograft Mouse Model
All animal studies were carried out according to the proposed 
protocol approved by the Seoul National University Institutional 
Animal Care and Use Committee (No. 150629-4-1). PC3 
prostate cancer cells were transfected with the luciferase-
IRES-EGFP or the luciferase-IRES-CITED2 plasmid and 
treated with G418 to select stable cell lines. Male 8 weeks old 
Balb/cSlc-nu/nu mice are used for orthopotic xenografts. We 
opened the low midline abdomen of mouse with 3-4 mm incision, 
and smoothly pressed the bladder using sterile cotton swab to 
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find the prostate. The PC3 stable cell lines were injected into the 
ventral lobe of prostate. After 14 days, shRNA lentiviruses were 
injected into grafted tumors, and tumor growth and metastasis 
were monitored using Xenogen IVIS® Lumina. 
Informatics analysis
Publicly available prostate cancer microarray dataset GSE6919 
was analyzed to compare CITED2 and nucleolin mRNA levels 
between normal and cancer tissues. All tissues (n = 171) were 
grouped as four classes: normal prostate tissues free of any 
pathological alteration (n=18), normal prostate tissues adjacent 
to tumors (n=63), primary prostate tumors (n=65), and 
metastatic prostate tumors (n=25). The values of the 33113_at 
probe (corresponding to CITED2), the 32590_at (corresponding 
to nucleolin) on each group were calculated and compared 
between the four groups using the Pearson correlation. The 
prostate cancer gene set enrichment analysis (GSEA) was also 
performed using GSE6919 data set, and a formatted GCT file was 
used as input for the GSEA algorithm v2.0 (available from: 
http://www.broadinstitute.org/gsea). For grouping the GSE6919 
data set, the values of the 33113 or 32590_at probe were used 
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as criteria standard for low expression and high expression 
group. CITED2 mRNA expression in 28 different type of cancer 
were obtained from using The Cancer Genome Atlas (TCGA), 
each cancer provisional data sets are based on generated by 
TCGA Research Network (http://cancergenome.nih.gov). The 
abbreviations used in Fig. 1a and the number of patients are as 
follows. ACC, Adrenocortical Carcinoma (n = 79); Bladder, 
Bladder Urothelial Carcinoma (n = 408); Glioma, Brain Lower 
Grade Glioma (n = 530); Breast, Breast Invasive Carcinoma (n 
=  1100); Cervical, Cervical Squamous Cell Carcinoma and 
Endocervical Adenocarcinoma (n = 306); Cholangiocarcinoma  
n = 36); Colorectal, Colorectal Adenocarcinoma (n =  382); 
GBM, Glioblastoma Multiforme (n = 166); Head & neck, Head 
and Neck Squamous Cell Carcinoma (n = 522); chRCC, Kidney 
Chromophobe (n = 66); ccRCC, Kidney Renal Clear Cell 
Carcinoma (n = 534); Liver, Liver Hepatocellular Carcinoma (n 
= 373); Lung adeno, Lung Adenocarcinoma (n = 517); Lung squ, 
Lung Squamous Cell Carcinoma (n = 501); DLBC, Lymphoid 
Neoplasm Diffuse Large B-cell Lymphoma (n = 48); 
Mesothelioma (n = 87); Ovarian, Ovarian Serous 
Cystadenocarcinoma (n = 307); Pancreas, Pancreatic 
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Adenocarcinoma (n = 179); PCPG, Pheochromocytoma and 
Paraganglioma (n = 184); Prostate, Prostate Adenocarcinoma (n 
= 498); Sarcoma (n = 263); Melanoma, Skin Cutaneous 
Melanoma (n = 472); Testicular Germ Cell, Testicular Germ Cell 
Cancer (n = 156); Thymoma (n = 120); Thyroid, Thyroid 
Carcinoma (n = 509); Uterine CS, Uterine Carcinosarcoma (n = 
57); Uterine, Uterine Corpus Endometrial Carcinoma (n = 177); 
Uveal Melanoma (n = 80).
Fractionation of cytoplasmic and nuclear components
Cells were spun down at 800 x g for 5 min, and gently 
homogenized in a hypotonic solution containing 20 mM Tris/HCl 
(pH 7.8), 1.5 mM MgCl2, 10 mM KCl, 0.2 mM EDTA, 0.5% NP-
40, 0.5 mM dithiotheritol, and 0.5 mM PMSF. The cell lysates 
were centrifuged at 3000 x g for 10 min at 4°C, and the 
supernatant was collected as the cytosolic fraction. The pellet 
was resuspended in a hypertonic solution containing 20 mM 
Tris/HCl (pH 7.8), 400 mM NaCl, 1 mM EDTA, 1.5 mM MgCl2, 
10% glycerol, 0.5 mM dithiotheritol, and 0.5mM PMSF, and 
intermittently vortexed on ice for 30 min. After the suspension 
was centrifuged at 18000 x g for 20 min at 4°C, the supernatant 
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was collected as the nuclear fraction.
Cell viability assay
Cells were grown in 98-well culture plates, and incubated with 
100 mL/well of the MTT labeling reagent (Sigma-Aldrich) for 3 
h. Blue formazan crystals were solubilized with acidified 
isopropanol, and formazan levels were determined at 570 nm. 
Fast protein liquid chromatography
FPLC analysis was performed on Preparative Biomolecular 
Purification System equipped with AKTA explorer 10 and 
Superdex 200 10/300 GL column (GE Healthcare, Uppsala, 
Sweden). After transfected with CITED2 or empty vector, the 
cells were centrifuged at 800 x g for 5 min, and resuspended 
with a lysis buffer consist of 20 mM Tris/HCl (pH 7.5), 150mM 
NaCl, 1 mM EDTA, 0.5% NP-40, 0.5 mM PMSF and protease 
inhibitor. The cell lysates were centrifugated at 4000 x g for 10 
minutes to separate into pellet and supernatant. Transfer 
supernatant and collect it for FPLC analysis. 100ml of protein 
elusion was continuously monitored at 280 nm using a UV 
detector. To estimate molecular weight of proteins in each 
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fraction, the Sigma-Aldrich FPLC protein markers (29 kDa -
700 kDa) were run on FPLC in the same condition. All 
procedures were carried out at 4°C. Each elute was subjected 
to immunoblotting with antibodies against nucleolin, PRMT5, 
WDR77, CITED2, P300, and RioK1. 
Migration and invasion assays
PC3 or DU145 cells were cultured in 24-well transwell plates 
with an 8.0-mm polycarbonate membrane which were purchased 
from Corning Life Science (Acton, MA). The lower chamber was 
filled with a culture medium containing 10% FBS as a chemo-
attractant. For cell migration analysis, PC3 or DU145 cells in an 
FBS-free medium were seeded into the upper chamber and 
incubated at 37°C for 12 h. For cell invasion analysis, the 
polycarbonate membrane was coated with 0.5 mg/ml of Matrigel. 
Cells on the upper surface of the interface membrane were 
removed using a cotton swab. Migrating cells on the lower 
surface of the membrane were stained with hematoxylin and 




Total RNA was isolated using TRIZOL reagent (Invitrogen; 
Carlsbad, CA), and cDNA synthesis was carried out in a reaction 
mixture (Promega, Madison, WI) containing M-MLV Reverse 
Transcriptase, RNase inhibitor, dNTP, and random primers at
46°C for 1 h. Quantitative real-time PCR on 96-well optical 
plates was performed in the qPCR Mastermix (Enzynomics, 
Daejeon, Korea), and fluorescence emitting from dye-DNA 
complex was monitored in CFX Connect Real-Time Cycler 
(BIO-RAD, Hercules, CA). The mRNA values of targeted genes 
were calculated relative to GAPDH expression. All reactions 
were performed in triplicate. The nucleotide sequences of PCR 
primers are summarized in Table 2.
RNA inmunoprecipitation
RNA immunoprecipitation (RIP) was conducted using the Magna 
RIPTM RNA-binding protein immunoprecipitation kit (EMD 
Millipore, Billerica, MA). Cells were spun down and homogenized 
in a RIP lysis buffer containing a protease inhibitor cocktail and 
RNase inhibitor. After cell lysates were centrifuged at 18000 x 
g for 10 min, the supernatant was incubated with IgG or anti-
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nucleolin antibody in RIP inmmunoprecipitation buffer overnight 
at 4°C, followed by incubation with protein A/G magnetic beads. 
The immune complexes were precipitated using a magnetic 
separator, and incubated in a protein degradation buffer 
containing 10% SDS and proteinase K at 55°C for 30 min. The 
samples were mixed with 400 mL of phenol:chloroform:isoamyl 
alcohol and centrifuged at 18000 x g for 10 min to separate the 
phases. The aqueous phase (350 mL) was mixed with 400 mL of 
chloroform, and centrifuge at 18000 x g for 10 min. The aqueous 
phase (300 mL) was mixed with 50 mL of salt solution I/II, 5 mL 
of precipitation enhancer and 850 mL of absolute ethanol, and 
centrifuged at 18000 x g for 30 min at 4°C. The pellet was 
washed with 80% ethanol, and resolved in 20 mL of RNase-free 
water. The level of AKT mRNA in the sample was quantified by 
RT-qPCR and represented as percentage of IP/input signal (% 
input). All reactions were performed in triplicate.
Chromatin immunoprecipitation (ChIP)
Cells were fixed with 37% formaldehyde at 37°C for 10 min, 
treated with 150 mM glycine. Fixed cells were lysed with 0.5% 
NP-40, and centrifuged at 800 x g at 4°C for 10 min to collect 
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crude nuclear fraction. Nucleus pellet was incubated with 1% 
SDS and sonicated to shear genomic DNAs into 300-500bp 
fragments. Soluble chromatin complexes were 
immunoprecipitated with IgG or anti-ERG antibody overnight at 
4°C. Immune complexes were precipitated with protein A/G 
beads pre-blocked by salmon sperm DNA at 4°C for 4 h. The 
beads were sequentially washed with a low salt buffer, a high salt 
buffer, LiCl wash buffer, and TE buffer. The immunoprecipitation 
chromatin complexes were eluted in a ChIP direct elution buffer 
at 65°C for 30 min and incubated overnight at 65°C to cross-
link chromatin complex. DNAs were isolated by phenol-
chloroform-isoamylalcohol (25:24:1) and precipitated with 
ethanol and glycogen. The extracted DNAs were resolved in 
nuclease-free water and analyzed by real-time PCR 
(95°C/55°C/72°C, 30 sec at each phase). 
Statistical analysis
All data were analyzed using Microsoft Excel 2013 software or 
Graph pad Prism 5 software, and results were expressed as 
means and standard deviations. I used the unpaired, two-sided 
Student t-test or Mann-Whitney U test to compare protein 
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expression level, mRNA expression level, cell viability, ROI flux, 
and cell numbers. Statistical significances were considered when 
P values were less than 0.05. And also, Protein or mRNA 
expression correlations were analyzed using a Spearman’s p 
statistic, Survival rate analysis were performed by drawing 
curves and calculating log-rank P test using The Kaplan-Meier 
method.
Data availability
The authors declare that all data supporting the findings of this 
study are available within the article and its supplementary 
information files or from the corresponding author upon 
reasonable request. Raw data file for LC-MS/MS is included in 
Table 1. Raw data files for RNA-seq have been deposited in the 




CITED2 is highly expressed in metastatic prostate cancer. 
I examined CITED2 expression in 28 different types of cancer 
using the TCGA database and found relatively high CITED2 
mRNA levels in thyroid, kidney, ovarian, lung, prostate, breast, 
and lung cancers (Fig. 1A). I next compared CITED2 levels 
between normal and cancer tissues using the Genomic Spatial 
Event (GSE) database. Of six types of cancers evaluated, 
CITED2 was elevated only in prostate cancer compared with 
normal tissue (Fig. 1B). Prostate cancer patients from the TCGA 
database were categorized into CITED2_low and CITED2_high 
groups with respect to the median CITED2 expression value. 
Overall survival was lower in the CITED2_high group than in the 
CITED2_low group (Fig. 1C). In thyroid, ovarian, lung, and breast 
cancers, CITED2 expression was not correlated with overall 
survival (Fig. 2A). In renal cell carcinoma (RCC), the 
CITED2_high group showed a longer survival than that of the 
CITED2_low group. To examine the involvement of CITED2 in
prostate cancer progression, I determined CITED2 expression in 
primary tumor and metastatic tumor tissues and found that 
CITED2 expression was increased in metastatic tumors (Fig. 
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1D). CITED2 expression in other types of cancers was not 
significantly increased with tumor stage (Fig. 2B). To evaluate 
CITED2 expression at the protein level, immunohistochemistry 
(IHC) using an anti-CITED2 antibody was performed in human 
prostate cancer tissues, which were categorized according to 
their Gleason score. Increased CITED2 protein levels were 
associated with an increasing Gleason score (Fig. 3A). When the 
prostate cancer tissues were divided into the CITED2_high and 
CITED2_low groups, a lower tumor-free survival was evident in 
CITED2_high compared with CITED2_low (Fig. 3B). CITED2 
expression might correlate with poor prognosis in prostate 
cancer patients.
ERG increases CITED2 expression at transcription level in 
prostate cancer. 
The ETS genes are fused to the promoters of the androgen 
receptor target genes, leading to their high expression in 
prostate cancer cells (3, 34). Because ELK1 in the ETS family 
has been reported to transactivate the CITED2 gene (19, 35), I
examined which member in the ETS family is responsible for 
CITED2 gene activation in prostate cancer. I compared the 
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mRNA levels of ETS members between normal prostate and 
prostate cancer tissues using the GSE6919 prostate cancer data 
set (Fig. 4A). Among those mRNAs, the ETS-related gene (ERG) 
level increased to the greatest extent in cancer tissues (Fig. 4B). 
The rate of gene fusion was highest to ERG among the ETS 
members according to the TCGA mutation sequence data (Fig. 
5A). Immunoblotting analysis in various prostate cancer cell lines 
showed an apparent correlation between ERG and CITED2 
expressions (Fig. 5B). Of the examined cell lines, VCaP 
harboring the TMPRSS2-ERG gene fusion expressed both ERG 
and CITED2 in the highest levels. When ERG was knocked down 
using three different siRNAs, the CITED2 protein and mRNA 
expression were both significantly downregulated in three cell 
lines, indicating ERG-dependent expression of CITED2 (Fig. 5C, 
5D). In prostate cancer cells harboring the TMPRSS2-ERG 
fusion, ERG expression is known to be highly induced by 
testosterone. As expected, testosterone robustly induced ERG 
expression in VCaP cells, where CITED2 expression was 
subsequently increased. Such effects of testosterone were not 
observed in DU145 cells without the TMPRSS2-ERG fusion (Fig. 
6). To examine the ERG binding to the CITED2 promoter, I
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performed chromatin immunoprecipitation and quantitative PCR 
analyses. Among the three regions within the promoter, the 
second region was identified as an ERG-binding site (Fig. 7A). I
then constructed a luciferase reporter plasmid containing the 
CITED2 promoter. Compared to PC3 and DU145 with a lower 
level of ERG, three prostate cancer cell lines with high ERG 
expression had greater luciferase activity (Fig. 7B). In these cell 
lines, CITED2 promoter activity was diminished by knocking-
down ERG or by mutating the putative ERG binding motif (Fig. 
7C). Next, I performed IHC to characterize ERG expression in 
prostate cancer tissues. The ERG level in prostate cancer 
increased with the Gleason score (Fig. 8A). Tumor-free survival 
in the ERG_high group was significantly lower compared with the 
ERG_low group (Fig. 8B). Pearson’s correlation analyses 
showed that CITED2 expression was positively correlated with 
ERG expression (Fig. 8C). Furthermore, I performed PCR using 
DNAs extracted from prostate cancer tissues and detected 
TMPRSS2-ERG gene fusion in 15 of 49 prostate cancers (Fig. 
9A). A chi-square test revealed that TMPRSS2-ERG gene 
fusion is associated with a high Gleason score (Fig. 9B). ERG and 
CITED2 overexpression in the TMPRSS2-ERG gene fusion 
31
samples (Fig. 9C) further support the ERG-driven 
overexpression of CITED2 in prostate cancer cells.
CITED2 binds to a multimeric complex consisting of nucleolin, 
p300, and PRMT5. 
To identify the CITED2-interacting proteins, I pulled down the 
FLAG/SBP-tagged CITED2 construct that was overexpressed in 
HEK293T cells using anti-FLAG or streptavidin affinity beads, 
and analyzed the co-purified proteins using LC-MS/MS. 
Proteins pulled down commonly by anti-FLAG antibody (red) 
and streptavidin (blue) are listed in Table 1. In addition to p300 
and CBP, the PRMT5 complex subunits PRMT5, WDR77, and 
RIOK1, as well as nucleolin were co-purified with CITED2 (Fig. 
10A). The interaction between PRMT5 and CITED2 was verified 
by immunoprecipitation and immunoblotting using HEK293T 
cells co-expressing MYC-PRMT5 and Flag/SBP-CITED2 (Fig. 
10B). I analyzed the interactions among endogenous PRMT5, 
nucleolin, WDR77, RIOK1, and CITED2 and found that CITED2 
and PRMT5 both interacted with nucleolin, WDR77, and RIOK1 
(Fig. 11A). These protein interactions were confirmed in the 
immunoprecipitates using nucleolin, WDR77, or RIOK1 
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antibodies (Fig. 11B). As previously shown in HEK293T cells, 
these interactions were also identified in all prostate cancer cell 
lines examined (Fig. 12). To verify the presence of this 
multimeric complex, I separated intracellular proteins using fast 
protein LC. Standard protein markers were used to determine the 
molecular weight of each fraction (Fig. 13A). CITED2, PRMT5, 
nucleolin, WDR77, Riok1, and p300 were detected in the ~500 
kDa fraction. Importantly, when CITED2 was overexpressed, the 
complex was shifted to ~700 kDa (Fig. 13B), which suggested 
that CITED2 plays a role in attracting proteins to the complex. 
To examine if CITED2, nucleolin, P300, and PRMT5 are directly 
associated, an in vitro binding assay was conducted using 
recombinant proteins. CITED2 directly interacted with nucleolin, 
P300 and PRMT5, while PRMT5 did not bind to P300 and 
nucleolin. Nucleolin and P300 were also bound directly (Fig. 14). 
Next, I performed immunofluorescent staining to determine the 
subcellular location of the proteins. The subunits in the complex 
were co-localized mainly in the nuclei of PC3 (Fig. 15A) or 
HEK293T cells (Fig. 15B). The interaction between PRMT5 and 
CITED2 was further characterized by immunoprecipitation of the 
domain peptides of CITED2 and PRMT5. p300, PRMT5, and 
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nucleolin were identified to bind to the transactivation domain 
(TAD), the serine/glycine-rich junction (SRJ), and the 
cysteine/arginine-rich domain 3 (CR3) of CITED2, respectively 
(Fig. 16A, 16B). In addition, CITED2 interacted with the N-
terminus of PRMT5 (Fig. 17). Since CITED2 provides different 
binding sites for p300, PRMT5 and nucleolin, these proteins 
could form a stable complex in a noncompetitive manner. 
Therefore, I hypothesized that CITED2 acts as an essential 
binder to make the multimeric complex. 
CITED2 modulates translocation of nucleolin through methylation 
and acetylation.
To examine whether CITED2 affects the subcellular localization 
of these subunits by forming a complex, I evaluated each subunit 
in the nuclear and cytoplasmic fractions of HEK293T cells 
overexpressing CITED2. CITED2 overexpression reduced 
nuclear expression of nucleolin but enhanced cytoplasmic 
expression, which was attenuated by a nuclear export inhibitor 
Leptomycin B (Fig. 18). This suggests that CITED2 induces the 
nuclear export of nucleolin. To determine role of CITED2 in the 
PRMT5/p300/nucleolin complex, immunoprecipitation was 
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performed using HEK293T cells with either CITED2 
overexpression or silencing. Notably, PRMT5 and p300 binding 
to nucleolin were potentiated by CITED2 overexpression but 
weakened by CITED2 knockdown (Fig. 19). This result 
prompted us to determine whether CITED2 acts as a molecular 
chaperone to guide PRMT5 and p300 to nucleolin. As expected, 
nucleolin was arginine-dimethylated and lysine-acetylated by 
PRMT5 and p300, respectively (Fig. 20A, 20B). More 
importantly, both modifications were dependent on CITED2 (Fig. 
21A, 21B). The CITED2-dependent modifications of nucleolin
were attenuated by PRMT5 and p300 knockdown (Fig. 22A, 
22B), which supports our hypothesis that CITED2 promotes 
post-translational modifications of nucleolin by recruiting 
PRMT5 and p300. Our next objective was to determine the 
subcellular location where CITED2-facilitated nucleolin
modification occurs. The CITED2-dependent modifications of 
nucleolin were detected in the nuclear fraction, which was 
expected since nucleolin is present mainly in the nucleus (Fig. 
23). Although the level of nucleolin protein was low in the 
cytoplasmic fraction compare to nuclear fraction, surprisingly, 
the dimethylated and acetylated nucleolin forms were clearly 
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detected in the same fraction (Fig. 23). The nuclear export of 
nucleolin was promoted by CITED2 overexpression, which was 
reversed by a PRMT5 inhibitor EPZ015666 (Fig. 24). These 
results suggest that nucleolin is modified in the nucleus and then 
translocated to the cytoplasm in part. The EGR-CITED2-
PRMT5/p300-nucleolin pathway is summarized in Fig. 25. 
The CITED2-nucleolin axis positively regulates EMT and cell 
migration in prostate cancer. 
The cellular consequences of the CITED2-nucleolin axis were 
examined using gene set enrichment analyses. Prostate cancer 
tissues in the GSE6919 dataset were divided into low and high 
expression groups based on the mean CITED2 and nucleolin
expression values (Fig. 26A). I identified the gene sets that were 
enriched in the high group compared with the low group (Fig. 
26B). Several metastasis-related gene sets were among the top 
10 gene sets enriched in the CITED2_high and nucleolin_high 
groups. To determine the role of the CITED2-nucleolin axis in 
cellular processes, I searched for gene sets commonly 
associated with CITED2 and nucleolin. Five of the top 10 common 
gene sets were related to metastasis (Fig. 27A). The enrichment 
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profiles of two representative gene sets associated with CITED2 
and nucleolin expression are shown in Fig. 27B and those of other 
gene sets in Fig. 28A, 28B. To support the patient-derived gene 
set enrichment data, I conducted RNA-seq analysis in PC3 cells. 
CITED2 was knocked down in PC3 cells using siRNAs (Fig. 29A). 
To observe changes in gene expression pattern by CITED2 
knockdown, heat map clustering was performed (Fig. 29B). I
found that metastasis-related gene sets were more enriched in 
the control group than in the CITED2 knockdown group (Fig. 
29C). Based on these results, I evaluated whether the CITED2-
nucleolin axis is involved in prostate cancer cell migration. In 
phalloidin-stained PC3 and DU145 cells, lamellipodia were 
formed depending on CITED2 expression (Fig. 30A). The 
CITED2 and nucleolin expression levels in the cells were verified 
by Western blotting (Fig. 30B). And then, In Transwell®
migration and invasion assays, CITED2 stimulated cell migration 
and invasion in a nucleolin-dependent manner (Fig. 30C and Fig. 
30D). In addition, CITED2 increased the protein and mRNA 
levels of mesenchymal markers but decreased those of epithelial 
markers, and these effects of CITED2 were attenuated by 
knocking-down nucleolin (Fig. 31A, 31B). However, CITED2 or 
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nucleolin expression did not affect cell growth or viability in 
prostate cancer cells (Fig 32A-C). Taken together, these 
results strongly suggest that the CITED2-nucleolin axis 
enhances the metastatic potential, rather than cell growth, in 
prostate cancer cells. 
The CITED2-nucleolin axis promotes prostate cancer metastasis 
in mice. 
To characterize the in vivo role of the CITED2-nucleolin axis 
in metastasis, I established stable PC3 cell lines and implanted 
them into the prostates of male athymic nude mice (Fig. 33A). 
CITED2 overexpression (Fig. 33B), luciferase activity (Fig. 
33C), and the degree of cell migration (Fig. 33D) were assessed 
in PC3 stable cell lines. The gene-silencing efficacies of 
lentiviruses harboring five different shRNAs targeting CITED2 
or nucleolin were evaluated by Western blotting (Fig. 33E). The 
abdomens of the mice were opened 2 months after cell 
implantation, revealing strong growth of the xenografted tumors 
in the prostates (Fig. 34A). In tumor tissue homogenates 
obtained from mouse xenograft, protein expressions of CITED2 
and nucleolin were measured to verify the overexpression or 
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knockdown of CITED2 and nucleolin (Fig. 34B). I monitored the 
bioluminescence emitted from cancer cells each week to trace 
the metastatic growth of the prostate tumors (Fig. 35). 
Compared with the control group, metastasis was enhanced in 
the CITED2-overexpressing group but reduced in the CITED2 
knockdown group. The metastasis-promoting effect of CITED2 
overexpression was abolished by nucleolin knockdown (Fig. 
36A). Integrated values of ROI luminescence were used in 
statistical analyses of tumor growth and metastasis. The results 
showed that prostate tumor growth was delayed by CITED2 or 
nucleolin knockdown (Fig. 36B). Metastasis was significantly 
enhanced by CITED2 overexpression, and this effect was 
reversed by nucleolin knockdown (Fig. 37A). Furthermore, 
mouse survival was decreased by CITED2 overexpression but 
rescued by CITED2 or nucleolin knockdown (Fig. 37B). The 
CITED2 overexpression group showed significant body weight 
loss, suggesting that these mice might be cachectic (Fig. 37C). 
Representative images of liver metastases are shown in Fig. 37D. 
Based on these results, the CITED2-nucleolin axis may activate 
signaling pathway(s) that strongly induce cancer metastasis. 
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CITED2-activated nucleolin promotes the AKT-driven EMT by 
enhancing translation of AKT mRNA. 
To explore the signaling pathway responsible for nucleolin-
mediated EMT, I performed proteomic analyses of 
phosphoproteins and found that phospho-AKT was reduced 
most in nucleolin-knockdown cells (Fig. 38A, 38B). Nucleolin
knockdown downregulated the protein levels of total AKT as well 
as phospho-AKT in prostate cancer cells (Fig. 39A), which 
occurred without any change in AKT mRNA levels (Fig. 39B). 
The CITED2-nucleolin axis was shown to affect the levels of 
AKT and phospho-AKT (Fig. 39C, 39D). CITED2 
overexpression facilitated de novo synthesis of the AKT protein 
(Fig. 40A) but did not stabilize the protein (Fig. 40B). Moreover, 
mRNA processing genes were enriched in cells with altered 
CITED2 or nucleolin expression (Fig. 41A). These results 
prompted us to evaluate whether the CITED2-nucleolin axis 
regulates the translation of AKT mRNA. I immunoprecipitated 
nucleolin using anti-nucleolin antibody and quantified the amount 
of co-precipitated AKT mRNA by quantitative RT-PCR. The 
nucleolin–AKT mRNA interaction was enhanced by CITED2 
overexpression but reduced by CITED2 knockdown (Fig. 41B). 
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Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA 
was used as a negative control to verify the specificity of RNA 
immunoprecipitation. Because the interaction between nucleolin
protein and AKT mRNA was attenuated by silencing PRMT5 or 
P300 even under CITED2 overexpression (Fig. 41C), CITED2 
may have enhanced the nucleolin–AKT mRNA interaction via 
PRMT5-mediated methylation and P300-mediated acetylation 
of nucleolin. To check whether cell migration was stimulated due 
to enhancement of AKT translation mediated by CITED2, 
migration assay was conducted with AKT knockdown and 
CITED2 overexpression (Fig. 42A). Compared to the control, 
CITED2 overexpression increased migration in PC3 and DU145 
cells, which was attenuated by AKT knockdown (Fig. 42B). 
Using three different PI3K inhibitors (Wortmannin, LY294002, 
and MK2206), I examined whether the AKT signaling pathway 
mediates CITED2-induced cell migration. As previously shown 
in Fig. 30C, CITED2-dependent cell migration was almost 
completely attenuated by each of these inhibitors (Fig. 43). In a 
similar manner, mRNA markers (Fig. 44A) and EMT protein (Fig. 
44B) were no longer regulated by CITED2. Because AKT 
signaling promotes SNAIL expression via NF-kB activation (36), 
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I examined whether NF-kB mediates the CITED2-AKT-EMT 
signaling. CITED2-dependent cell migration and invasion both 
were abolished by an NF-kB inhibitor Bay-11-7082 (Fig. 45). 
IHC was used to determine if AKT is activated in prostate cancer 
tissues. Phospho-AKT expression increased concomitantly with 
an increase in the Gleason score (Fig. 46A) and was associated 
with poor survival of patients with prostate cancer (Fig. 46B). 
Pearson’s correlation analyses revealed a significant positive 
correlation between phospho-AKT and CITED2 levels (Fig. 
46C).
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Figure 1. CITED2 is overexpressed in prostate cancer.
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Figure 1. CITED2 is overexpressed in prostate cancer.
(A) CITED2 mRNA expression in 28 different type of cancer as 
determined by RNA Seq V2 RSEM. Box plots indicate the 
distribution of values and the middle thick line in the box shows 
mean value and whiskers represent 10-90 percentile. Results 
were obtained from using The Cancer Genome Atlas (TCGA), 
each cancer provisional data sets are based on generated by 
TCGA Research Network (http://cancergenome.nih.gov). The 
abbreviations and the number of patients are described in the 
method section. (B) CITED2 mRNA levels in normal (blue 
squares) and cancer tissues (red triangles) of thyroid, kidney, 
ovarian, lung, prostate, and breast (GSE datasets). (C) Kaplan-
Meier overall survival analysis of prostate cancer patients on 
TCGA. P-value was calculated by Log-rank Test. (D) CITED2 
mRNA levels in human prostate cancer tissues of data set 
GES6919. N, normal prostate tissue (blue squares); A, normal 
prostate tissue adjacent tumor tissue (green triangles); PT, 
prostate primary tumor tissue (black inverted triangles); MT, 
metastatic prostate tumor tissue (red diamond). The horizontal 
lines in all dot plots represent the means ± s.e.m. and # denotes 
P < 0.05 versus the normal tissue group by Mann-Whitney 
statistical analysis.
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Figure 2. CITED2 expression does not correlate with the overall 
survival and the tumor stage in thyroid, ovarian, lung, and breast 
cancer. 
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Figure 2. CITED2 expression does not correlate with the overall 
survival and the tumor stage in thyroid, ovarian, lung, and breast 
cancer. 
(A) Kaplan-Meier overall survival analysis of thyroid, lung, 
kidney, breast and ovarian cancer patients. P-value was 
calculated by Log-rank test. (B) CITED2 mRNA levels 
according to tumor stages in human thyroid, lung, kidney, breast, 
and ovarian cancer tissues. Dot plots indicate the distribution of 
values, and the horizontal lines are the mean ± s.e.m. # denotes 
P < 0.05 versus the T1 group by Mann-Whitney statistical 
analysis. T1, blue squares; T2, green triangles; T3, black 
inverted triangles; T4, red diamond. Data were obtained from 
using The Cancer Genome Atlas (TCGA).
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Figure 3. CITED2 protein expression is associated with poor 
prognosis in prostate cancer.
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Figure 3. CITED2 protein expression is associated with poor 
prognosis in prostate cancer.
(A) Representative images of human prostate adenocarcinoma 
tissues immunostained with anti-CITED2 antibody. 
Abbreviations at the left bottoms of images: N, normal prostate 
tissue (blue squares); G6~10 (6-7, green triangles; 8, black 
inverted triangles; 9-10, red diamond) Gleason scores 6~10 of 
prostate cancer (left panel). The immunostaining scores were 
calculated by counting stained cells and presented as dot plots 
(right panel). The scale bar represents 50mm. (B) Kaplan-Meier 
tumor-free survival analysis of prostate cancer patients. P-
value was calculated by Log-rank Test. The horizontal lines in 
all dot plots represent the means ± s.e.m. and # denotes P < 0.05 
versus the normal tissue group by Mann-Whitney statistical 
analysis.
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Figure 4. ERG level is the most increased in prostate cancer tissue.
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Figure 4. ERG level is the most increased in prostate cancer tissue.
(A) The mRNA levels of the ETS family members in GSE6919 
dataset. Each bar represents the ratio of tumor level to normal 
level. (B) Comparison of ETS gene family mRNA expression 
between normal and cancer prostate tissues, which were 
obtained from data set GES6919. Nor, normal prostate tissue (N 
= 19, blue squares); PCa, prostate tumor tissue (N = 90, red 
triangles). The horizontal lines represent the mean ± s.e.m., # 
denotes P < 0.05 versus the normal prostate group by Mann-
Whitney statistical analysis.
50
Figure 5. CITED2 is up-regulated due to the TMPRSS2-ERG 
gene fusion in prostate cancer.
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Figure 5. CITED2 is up-regulated due to the TMPRSS2-ERG 
gene fusion in prostate cancer.
(A) The circular chart shows mutation subtypes identified in 333 
prostate cancer patients. Data were obtained from TCGA 
(Prostate Adenocarcinoma, Cell 2015). (B) Lysates of prostate 
cancer cell lines were immunoblotted with anti-ERG, anti-
CITED2, or anti-b-tubulin antibody. (C) Indicated cells were 
transfected with non-targeting siRNA (si-Con) or three 
different ERG-targeting siRNAs (si-ERG #1, #2 and #3) at an 
80 nM concentration. Cell lysates were immunoblotted using the 
indicated antibodies. (D) RT-qPCR was performed to analyze 
CITED2 mRNA levels in prostate cancer cells transfected with 
the indicated siRNAs. Each bar represents the mean + s.d. (n=3).
* denotes P < 0.05 versus the si-Con group by Student’s t-
test.
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Figure 6. Testosterone induced CITED2 expression in VCaP cells.
VCaP and DU145 cells were treated with testosterone, and the 










Figure 7. ERG binds and activates the CITED2 promoter. 
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Figure 7. ERG binds and activates the CITED2 promoter.
(A) The ERG binding to three CITED2 promotor regions (P1, P2 
and P3) was detected by ChIP-qPCR using anti-ERG antiserum 
or non-immunized serum (IgG). The co-precipitated CITED2 
promotor regions was quantified using RT-qPCR. Results (the 
mean ± s.d., n=3) were represented as percentages of IP 
signal/input signal (% input). * denote P < 0.05 versus the IgG 
control group. (B) The activities of the CITED2 promoter-
luciferase reporter. Prostate cancer cells were transfected with 
the reporter plasmid. Luciferase activities (the mean + s.d., n=3) 
were measured by a luminometer. (C) The indicated siRNAs 
were co-transfected with the CITED2-luciferease or 
CITED2_mEBS (mutated ERG-binding sequence, patterned) 
reporter plasmid. Luciferase activities (mean + s.d., n=3) were
measured by a luminometer. * denotes P < 0.05 versus the si-
Con group by Student’s t-test and N.S. does ‘not significantly 
different’ among the groups.
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Figure 8. ERG protein expression is associated with poor 
prognosis in prostate cancer.
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Figure 8. ERG protein expression is associated with poor 
prognosis in prostate cancer.
(A) Representative images of human prostate adenocarcinoma 
tissues immunostained with anti-ERG antibody. Abbreviations at 
the left bottoms of images: N, normal prostate tissue (blue 
squares); G6~10 (6-7, green triangles; 8, black inverted 
triangles; 9-10, red diamond) Gleason scores 6~10 of prostate 
cancer (left panel). The immunostaining scores were calculated 
by counting stained cells and presented as dot plots (right panel). 
The scale bar represents 50mm. The horizontal lines represent 
the mean ± s.e.m., # denotes P < 0.05 versus the normal prostate 
group by Mann-Whitney statistical analysis. (B) Kaplan-Meier 
tumor-free survival analysis of prostate cancer patients. P-
value was calculated by Log-rank Test. (C) Protein expression 
scatter diagrams of ERG versus CITED2. Linear regression and 
correlation of ERG versus CITED2. R-square (R2) means 
coefficient of determination calculated by Pearson’s correlation. 
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Figure 9. The TMPRSS2-ERG gene fusion support the ERG-
driven overexpression of CITED2 in patient tissues.
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Figure 9. The TMPRSS2-ERG gene fusion support the ERG-
driven overexpression of CITED2 in patient tissues.
(A) DNAs extracted from prostate cancer tissues were 
subjected to PCR using a forward primer binding to the 
TMPRSS2 promoter and a reverse primer binding to the ERG
gene. The PCR products of the TMPRSS2-ERG fusion gene (+, 
positive; -, negative) are indicated as an arrow. (B) Distribution 
of the TMPRSS2:ERG fusion according to the prostate cancer 
Gleason score was statistically analyzed using chi-square test. 
(C) The immunostaining scores were calculated by counting 
stained cells. Blue and red symbols indicate ERG (right panel) 
and CITED2 (left panel) levels in the TMPRSS2-ERG fusion 
negative (blue squares) and positive (red triangles) group. The 
horizontal lines in all dot plots represent the means ± s.e.m. and 
# denotes P < 0.05 versus the normal group by Mann-Whitney 
statistical analysis. 
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Figure 10. P300 and nucleolin, the PRMT5 complex subunits 
PRMT5, WDR77, and RIOK1 were co-purified with CITED2.
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Figure 10. P300 and nucleolin, the PRMT5 complex subunits 
PRMT5, WDR77, and RIOK1 were co-purified with CITED2.
(A) HEK293T cells were transfected with the Flag/SBP-
CITED2 plasmid. CITED2-interacting proteins were precipitated 
using anti-Flag tag antibody or streptavidin, and identified by 
LC-MS/MS analyses. The proteins identified commonly in two 
precipitates are listed. 
(B) HEK293T cells were cotransfected with Flag/SBP-CITED2 
and Myc-PRMT5. Proteins in cell lysates were 
immunoprecipitated with anti-Myc, anti-Flag, or IgG, and the 
precipitates were immunoblotted with the indicated antibodies.
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Figure 11. CITED2 is included in the multimeric complex of 
nucleolin.
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Figure 11. CITED2 is included in the multimeric complex of 
nucleolin. (A) HEK293T cell lysates were immunoprecipitated 
with anti-PRMT5 antibody or anti-CITED2 or IgG, and the 
precipitates were immunoblotted with the indicated antibodies. 
(B) HEK293T cell lysates were immunoprecipitated with anti-
nucleolin, anti-WDR77, anti-RioK1 antibody, or IgG, followed 
by immunoblotting with the indicated antibodies.
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Figure 12. CITED2 interacts with P300 and PRMT5 complex in 
prostate cancer cells.
Prostate cancer cell lysates were immunoprecipitated with anti-
CITED2 antibody or IgG, and the precipitates were 
immunoblotted with the indicated antibodies.
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Figure 13. CITED2 forms a multimeric complex with nucleolin, 
p300, and PRMT5 subuints.
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Figure 13. CITED2 forms a multimeric complex with nucleolin, 
p300, and PRMT5 subuints.
(A) Standard protein markers used for FPLC analysis with 
Superdex™ 200 column. (B) HEK293T cells were transfected 
with pcDNA or CITED2, and the cell lysates were subjected to 
FPLC. The FPLC elutes were immunoblotted with the indicated 
antibodies. The red box indicates a bigger-sized complex (600 
to 700 kDa) that is formed by CITED2 overexpression.
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Figure 14. CITED2 directly interacted with nucleolin, P300 and 
PRMT5.
In vitro binding analysis. Recombinant protein CITED2, PRMT5, 
nucleolin, P300 were put together in a test tube. Proteins in tube 
were immunoprecipitated with indicated antibodies, and the 
precipitates were immunoblotted. Input levels were verified by 
electrophoresis and Coomassie staining.
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Figure 15. The subunits in the complex were co-localized mainly 
in the nuclei of PC3 and HEK293T cell.
A
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Figure 15. The subunits in the complex were co-localized mainly 
in the nuclei of PC3 and HEK293T cell.
B
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Figure 15. The subunits in the complex were co-localized mainly 
in the nuclei of PC3 and HEK293T cell.
(A) Representative immunofluorescence images. PC3 cells were 
grown on coverslips, fixed with methanol, and stained with the 
indicated antibodies. All samples were stained with DAPI to 
visualize nuclei. The scale bar represents 20mm. (B)
Representative immunofluorescence images. HEK293T cells 
were grown on coverslips, fixed with methanol, and stained with 
the indicated antibodies. All samples were stained with DAPI to 
visualize nuclei. The scale bar represents 20 mm.
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Figure 16. Different domain of CITED2 interacts with p300, 
PRMT5 and nucleolin.
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Figure 16. Different domain of CITED2 interacts with p300, 
PRMT5 and nucleolin.
(A) The Flag/SBP-CITED2 constructs are shown in the top 
panel. HEK293T cells were cotransfected with one of the 
CITED2 constructs and Myc-PRMT5, HA-P300 and Flag/SBP-
peptides were immunoprecipitated with anti-Flag and Myc-
PRMT5 and HA-P300 were detected by Western blotting. (B) 
HEK293T cells were transfected with the CITED2 constructs, 
and cell lysates were immunoprecipitated with anti-nucleolin and 
Flag/SBP-CITED2 peptides were detected by Western blotting.
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Figure 17. CITED2 interacted with the N-terminus of PRMT5.
The Myc-PRMT5 constructs are shown in the top panel. 
HEK293T cells were cotransfected with one of the PRMT5 
construct and Flag/SBP-CITED2, and Myc-peptides were 
immunoprecipitated with anti-Myc and Flag/SBP-CITED2 were 
detected by Western blotting.
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Figure 18. CITED2 overexpression enhanced cytoplasmic 
expression of nucleolin. HEK293T cells were transfected with 
pcDNA or CITED2 and treated with Leptomycin B (200 nM), and 
the cell lysates were fractionated to cytosoli and nuclear 
components. The cell fractions were immunoblotted with the 
indicated antibodies.
74
Figure 19. PRMT5 and p300 binding to nucleolin were potentiated 
by CITED2 overexpression.
HEK293T cells were cotransfected with Flag/SBP-nucleolin and 
CITED2 or si-CITED2. Cell lysates were immunoprecipitated 
with anti-Flag and immunoblotted with the indicated antibodies.
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Figure 20. Nucleolin was arginine-dimethylated and lysine-
acetylated by PRMT5 and p300.
(A) HEK293T cells were transfected with Myc-PRMT5 and/or 
si-PRMT5. Cell lysates were immunoprecipitated with anti-
dimethyl arginine antibody and precipitated nucleolin was 
immunoblotted. (B) HEK293T cells were transfected with HA-
p300. Cell lysates were immunoprecipitated with anti-acetyl 
lysine antibody and precipitated nucleolin was immunoblotted.
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Figure 21. Post-translational modifications of nucleolin were 
dependent on CITED2.
(A) HEK293T cells were cotransfected with Flag/SBP-nucleolin
and CITED2 or si-CITED2. Cell lysates were 
immunoprecipitated with anti-dimethyl arginine antibody and 
precipitated nucleolin was immunoblotted. (B) HEK293T cells 
were cotransfected with Flag/SBP-nucleolin and CITED2 or si-
CITED2. Cell lysates were immunoprecipitated with anti-acetyl 
lysine antibody and precipitated nucleolin was immunoblotted.
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Figure 22. The CITED2-dependent modifications of nucleolin
were attenuated by PRMT5 and p300 knockdown.
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Figure 22. The CITED2-dependent modifications of nucleolin
were attenuated by PRMT5 and p300 knockdown.
(A) HEK293T cells were cotransfected with the indicated 
plasmids and siRNAs. Cell lysates were immunoprecipitated with 
anti-dimethyl arginine antibody and precipitated nucleolin was 
immunoblotted. (B)HEK293T cells were cotransfected with the 
indicated plasmids and siRNAs. Cell lysates were 
immunoprecipitated with anti-acetyl lysine antibody and 
precipitated nucleolin was immunoblotted.
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Figure 23. The dimethylated and acetylated nucleolin forms were 
detected in the cytoplasmic fraction.
HEK293T cells were cotransfected with Flag/SBP-nucleolin and 
CITED2, and the cell lysates were fractionated to cytosoli and 
nuclear components. The cell fractions were immunoprecipitated 
with anti-Flag antibody and immunoblotted with the indicated 
antibodies.
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Figure 24. Translocation of nucleolin was decreased by a PRMT5 
inhibitor. 
HEK293T cells were transfected with pcDNA or CITED2 with 
EPZ015666 (5 mM), and the cell lysates were fractionated to 
cytosoli and nuclear components. The cell fractions were 
immunoblotted with the indicated antibodies.
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Figure 25. Graphical summary of The EGR-CITED2-
PRMT5/p300-nucleolin pathway in prostate cancer.
ERG is upregulated due to the TMPRSS2-ERG gene fusion and 
transactivates the CITED2 gene in prostate cancer cells. 
Overexpressed CITED2 induces the methylation and acetylation 
of nucleolin in the nucleus by recruiting PRMT5 and p300, then 
modified nucleolin is translocated to the cytoplasm. 
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Figure 26. CITED2 and nucleolin both are positively associated 
with high expression of metastasis-related gene sets. 
NES  1.8      2.0     2.2                
CITED2
Nucleolin
NES  1.6     1.9     2.2      
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Figure 26. CITED2 and nucleolin both are positively associated 
with high expression of metastasis-related gene sets. 
(A) Distribution of CITED2 (left) or nucleolin (right) mRNA 
levels in 171 human prostate tissues (data set GSE6919). Based 
on the mean values, the prostate cancer tissues were divided into 
high and low groups. The numbers of cancers are 52 in the 
CITED2 high, 119 in the CITED2 low, 72 in the nucleolin high, 
and 99 in the nucleolin low group. (B) Top 10 gene sets showing 
a positive correlation with CITED2 or nucleolin are ranked.
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Figure 27. Metastasis related gene sets commonly associated with 










Figure 27. Metastasis related gene sets commonly associated with 
CITED2 and nucleolin. 
(A) Gene Set Enrichment Analysis (GSEA). Venn diagram 
depicts 39 gene sets upregulated (P < 0.05 and FDR < 0.30) 
commonly by CITED2 and nucleolin expression. Of them, top 10 
gene sets are listed. (B) Representative enrichment plots of the 
metastasis-related gene set which positively correlate with 
CITED2 (left panel) or nucleolin (right panel).
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Figure 28. The enrichment profiles of gene sets associated with 
CITED2 and nucleolin expression.
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Figure 28. The enrichment profiles of gene sets associated with 
CITED2 and nucleolin expression.
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Figure 28. The enrichment profiles of gene sets associated with 
CITED2 and nucleolin expression.
(A) Enrichment plots of the top 10 gene sets that were positively 
correlated with CITED2 expression with P < 0.05 and FDR < 0.30.
(B) Enrichment plots of the top 10 gene sets that were positively 
correlated with nucleolin expression with P < 0.05 and FDR < 
0.30.
89






Figure 29. CITED2 promotes metastasis-related gene sets in PC3 
cells.
(A) PC3 cells were transfected with control or CITED2-
targeting siRNA. Total RNAs were extracted using Trizol and 
subjected to RNA-sequencing analyses. The experiments were 
performed three times independently. CITED2 was 
immunoblotted to verify knockdown. (B) Heat map of genes that 
were differentially expressed in si-Control group (n = 3) and 
si-CITED2 group (n = 3) with P-value < 0.05 and Fold change 
> 2. (C) The graphs show representative enrichment plots of the 
metastasis-related gene set which positively correlate with 







Figure 30. CITED2 promotes prostate cancer cell migration and 
invasion nucleolin-dependently.
(A) PC3 and DU145 cells were transfected with CITED2 or si-
CITED2, and stained with rhodamine phalloidin (red) and DAPI 
(blue). The scale bar represents 20mm. (B) CITED2 and 
nucleolin were immunoblotted to verify knockdown and 
overexpression. (C) Cell migration was analyzed using a trans-
well chamber. PC3 and DU145 cells (1x104/well), which had 
been transfected as indicated, were placed on the upper chamber. 
After 12 h, cells passing through the interface membrane were 
stained (top) and counted (bottom). Each bar represents the 
mean + s.d. (n=3). The scale bar represents 25mm. (C)
Representative trans-well membrane pictures of invasion assay. 
The transfected PC3 and DU145 cells (1x104 per well) were 
loaded in the upper chamber of the trans-well culture dish. After 
12 h, cells passing through a Matrigel-coated interface 
membrane were stained (left) and counted (right). Cells were 
stained and counted, which are presented as bar graphs. The 
scale bar represents 25 mm. * denotes P < 0.05 versus the control 
group and N.S. does ‘not significantly different’ among the groups 
by Student’s t-test.
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Figure 31. CITED2 increased the protein and mRNA levels of 
mesenchymal markers but decreased those of epithelial markers.
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Figure 31. CITED2 increased the protein and mRNA levels of 
mesenchymal markers but decreased those of epithelial markers.
(A) PC3 and DU145 cells were transfected with CITED2 or si-
CITED2, and/or si-nucleolin. Representative EMT markers were 
immunoblotted. (B) RNAs were extracted from PC3 or DU145 
cells which were transfected with CITED2 or si-CITED2 and/or 
si-nucleolin. The SNAIL and E-CAD mRNA levels were 
measured by RT-qPCR. Each bar represents the mean + s.d. 
(n=3). * denotes P < 0.05 versus the control group and N.S. does 
‘not significantly different’ among the groups by Student’s t-test.
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Figure 32. CITED2 or nucleolin expression did not affect cell 





Figure 32. CITED2 or nucleolin expression did not affect cell 
growth or viability in prostate cancer cells.
(A) Cell growth curves. PC3 or DU145 cells, which had been 
transfected with CITED2 or si-CITED2, were plated in 24-well 
culture dishes (5 x 104 per well) and counted at the indicated 
time. (B) Cell viabilities were measured using MTT. (C) Cell 
viabilities were measured using MTT. All results in the above 
graphs are presented as the means ± s.d. from three independent 
experiments and * denotes P < 0.05 versus the indicated control 
groups by Student’s t-test and N.S. does ‘not significantly 
different’ among the groups.
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Figure 33. Schematic diagram of in vivo mouse model and
verification of PC3 stable cell lines. 
A PC3-Luc or PC3-Luc-CITED2 
orthotopic injection
0day                                                 14day                                                 










Figure 33. Schematic diagram of in vivo mouse model and
verification of PC3 stable cell lines. 
(A) Schematic diagram of in vivo prostate metastasis model. (B) 
CITED2 proteins were immunoblotted in a PC3 stable cell line 
transfected with Luc-CITED2. (C) The luciferase activities in 
PC3 stable cell lines were measured using a luminometer. Each 
bar represents the mean + s.d., from 3 experiments. (D)
Representative pictures of trans-well membrane migration 
assays in PC3-Luc and PC3-Luc-CITED2 stable cell lines 
(left). Migrated cells were stained and counted (right). Each bar 
represents the mean + s.d., from 3 experiments. * denotes P < 
0.05 versus the indicated control groups by Student’s t-test. 
The scale bar represents 25 mm. (E) Efficacies of five different 
sequence shRNAs (#1 - #5) targeting CITED2 or nucleolin in 
PC3 cell lysates. Cell lystaes were immunoblotted with anti-
CITED2 or anti-nucleolin antibody. The shCITED2 #4 and the 
shnucleolin #1 were used in xenograft experiments.
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Figure 34. Verification of xenografted tumors and protein 
expressions.
(A) Representative photographs of prostate tumors 10 weeks 
after cell implantation. The luciferase-expressing PC3 cells (0.5
x 106) were suspended in 20 mL of sterile PBS and injected into 
the prostates of Balb/cSlc-nu/nu mice. (B) CITED2 and nucleolin










SI : Small Intestine
SV : Seminal Vesicle
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Figure 35. Bioluminescence images of mice having orthotopically 
grafted prostate cancer. 
Luciferase-expressing PC3 stable cell lines were injected into 
the prostates of mice. Bioluminescence images of live mice were 
monitored using Xenogen IVIS® Lumina 100 weekly for 7 weeks. 
Red arrows indicate metastasis tumors. Color scale bars 
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Figure 36. CITED2 promotes metastasis effect in vivo model.
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Figure 36. CITED2 promotes metastasis effect in vivo model.
(A) Bioluminescent images of primary tumors and metastases 
were monitored using Xenogen IVIS® Lumina 100. Color scale 
bars represent tumor intensity from purple (low) to red (high). 
(B) Growth curves of primary tumors were plotted based on 
bioluminescence intensities. Data are presented as the mean + 
s.d., and * denotes P < 0.05 between two groups by Mann-
Whitney statistical analysis. Mouse numbers are 8 in the sh-
EGFP group, 8 in the sh-CITED2 group, 11 in the CITED2 + 
sh-EGFP, and 7 in the CITED2 + sh-nucleolin group.
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Figure 37. The CITED2-nucleolin axis induce prostate cancer 
metastasis in vivo.
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Figure 37. The CITED2-nucleolin axis induce prostate cancer 
metastasis in vivo.
(A) Metastasis rate was retrieved according to the Kaplan-
Meier method and * denotes P < 0.05 between two groups. 
Metastasis was defined as ROI flux value was larger than 1.0 x 
e5. (B) Kaplan-Meier overall survival rate analyses were 
followed up until 80 days after xenograft and * denotes P < 0.05 
between two groups. (C) Tumor-bearing mice were weighed in 
the indicated times. Data are presented as the mean + s.d., and 
* denotes P < 0.05 between two groups by Mann-Whitney 
statistical analysis. (D) Representative photographs of livers 






























































Figure 38. Phospho-AKT was reduced most in nucleolin-
knockdown cells.
(A) PC3 cells were transfected with si-Con or si-nucleolin, and 
the cell lysates were subjected to the Proteome ProfilerTM
phospho-kinase array kit. The red boxes indicate blots of AKT 
phosphorylated at T308 and S473. (B) The blot spot pixel 
densities were analyzed by the ImageJ program.
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Figure 39. The CITED2-nucleolin axis was shown to affect the 





Figure 39. The CITED2-nucleolin axis was shown to affect the 
protein levels of AKT and phospho-AKT.
(A) Immunoblotting of nucleolin, AKT, p-AKT and b-tubulin in 
PC3 and DU145 cells that were transfected with si-Con or si-
nucleolin. (B) The AKT mRNA levels in PC3 and DU145 cells 
were measured by RT-qPCR. (C) Immunoblotting of nucleolin, 
CITED2, AKT, p-AKT and b-tubulin in cells that were 
transfected with CITED2 or si-CITED2 and si-nucleolin. (D) 
The AKT mRNA levels in cells were measured by RT-qPCR.
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Figure 40. CITED2 facilitated de novo synthesis of the AKT 
protein.
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Figure 40. CITED2 facilitated de novo synthesis of the AKT 
protein.
(A) DU145 cells, which had been transfected with pcDNA or 
CITED2, were pretreated with 100 mM cycloheximide for 12 h. 
After washing out cycloheximide, cells were incubated for the 
indicated times. AKT synthesis levels were detected by Western 
blotting and quantified using ImageJ. Each point represents the 
mean ± s.d. (n=3) (B) DU145 cells, which had been transfected 
with pcDNA or CITED2, were treated with 100 mM 
cycloheximide, and then cells were incubated for the indicated 
times. AKT levels were detected by Western blotting and 
quantified using ImageJ.
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Figure 41. The CITED2-nucleolin axis regulates the translation 
of AKT mRNA.
(A) Representative enrichment plots of the mRNA processing 
gene set which commonly correlates with CITED2 (left) and 
nucleolin (right). (B-C) RNA-IP was performed to analyze the 
nucleolin binding to AKT mRNA. DU145 cells were transfected 
as indicated and the cell lysates were immunoprecipitated with 
anti-nucleolin or IgG. The co-precipitated AKT or GAPDH (a 
negative control) mRNA was quantified using RT-qPCR. Results 
(the mean ± s.d., n=3) were represented as percentages of IP 
signal/input signal (% input).
113























































































Figure 42. CITED2 overexpression increased cell migration 
through AKT pathway.
(A) AKT and CITED2 proteins were immunoblotted to verify 
knockdown and overexpression. (B) Cells had been transfected 
with CITED2, and/or si-AKT, were subjected to cell migration 
assay. Cells passing through the interface membrane were 
stained and counted. The relative cell migration is presented as 
a bar graph (the mean + s.d., n=3) and * denotes P < 0.05 versus 
the control group and N.S. does ‘not significantly different’
among the groups by Student’s t-test. The scale bar represents 
25mm.
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Figure 43. CITED2-dependent cell migration was attenuated by 
PI3K inhibitors.
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Figure 43. CITED2-dependent cell migration was attenuated by 
PI3K inhibitors.
CITED2-activated nucleolin promotes the AKT-driven cell 
migration. Representative pictures of trans-well migration 
assays. The transfected cells were subjected to the cell 
migration assay in the presence of wortmannin (200 nM), 
LY294002 (25 mM), or MK2206 (2 mM). CITED2 and phospho-
AKT levels were analyzed by Western blotting.  Migrated cells 
were stained and counted, which are presented as bar graphs 
(means + s.d., n=3). N.S. represents ‘not significantly different’
among the indicated groups by Student’s t-test. The scale bar 
represents 25 mm.
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Figure 44. CITED2-dependent EMT marker alteration was 




Figure 44. CITED2-dependent EMT marker alteration was 
attenuated by PI3K inhibitors.
(A) PC3 and DU145 cells, which had been transfected with 
CITED2 or si-CITED2, were treated with wortmannin (200 nM), 
LY294002 (25 mM), or MK2206 (2 mM). The SNAIL and E-CAD
mRNA levels (means + s.d., n=3) were measured by RT-qPCR. 
N.S. represents ‘not significantly different’ among the indicated 
groups by Student’s t-test. (B) EMT markers were 
immunoblotted in PC3 and DU145 cells that were transfected 
with CITED2 or si-CITED2 and treated with wortmannin (200 
nM).
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Figure 45. CITED2 regulates cell migration via the NF-kB 
pathway.
Representative pictures of trans-well migration assays. The 
transfected cells were subjected to the cell migration assay in 
the presence of Bay 11-7082 (10 mM). Migrated cells were 
stained and counted, which are presented as bar graphs (means 
+ s.d., n=3). N.S. represents ‘not significantly different’ among 
the indicated groups by Student’s t-test. The scale bar 
represents 25 mm.
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Figure 46. Phospho-AKT expression is associated with poor 
prognosis of prostate cancer patients.
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Figure 46. Phospho-AKT expression is associated with poor 
prognosis of prostate cancer patients.
(A) Representative images of human prostate adenocarcinoma 
tissues immunostained with anti-phospho-AKT antibody. 
Abbreviations at the left bottoms of images: N, normal prostate 
tissue (blue squares); G6~10 (6-7, green triangles; 8, black 
inverted triangles; 9-10, red diamond) Gleason scores 6~10 of 
prostate cancer (left panel). The immunostaining scores were 
calculated by counting stained cells and presented as dot plots 
(right panel). The horizontal lines in dot plot represent the means 
± s.e.m. and # denotes P < 0.05 versus the normal group by 
Mann-Whitney statistical analysis. The scale bar represents 
50mm. (B) Kaplan-Meier tumor-free survival analysis of 
prostate cancer patients. P-value was calculated by Log-rank 
test. (C) Scatter diagrams for p-AKT expression versus 
CITED2 expression. R value means the Pearson’s correlation 
coefficient.
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Protein Score MW Accession Peptide 
actin, gamma 1 propeptide 30.19 41765.8 4501887 3
actin, gamma 1 propeptide 20.15 41765.8 4501887 2
albumin preproprotein 160.30 69321.6 4502027 32
albumin preproprotein 70.27 69321.6 4502027 9
apolipoprotein A-I preproprotein 40.22 30758.9 4557321 4
apolipoprotein A-I preproprotein 10.14 30758.9 4557321 1
apolipoprotein D precursor 30.23 21261.8 4502163 4
apolipoprotein D precursor 10.15 21261.8 4502163 1
apolipoprotein E precursor 30.23 36131.8 4557325 3
apolipoprotein E precursor 10.18 36131.8 4557325 1
apolipoprotein H precursor 20.18 38272.7 153266841 3
apolipoprotein H precursor 10.14 38272.7 153266841 1
apolipoprotein L1 isoform c precursor 10.21 42132.0 211938442 2
apolipoprotein L1 isoform c precursor 10.14 42132.0 211938442 1
astrotactin 2 isoform d 10.15 44532.1 38016949 1
astrotactin 2 isoform d 10.13 44532.1 38016949 1
ATP-dependent DNA helicase II 10.12 82652.4 10863945 1
ATP-dependent DNA helicase II 10.12 82652.4 10863945 1
ATP-dependent DNA helicase II, 70 kDa subunit 10.18 69799.2 4503841 1
ATP-dependent DNA helicase II, 70 kDa subunit 20.13 69799.2 4503841 2
carbamoylphosphate synthetase 2/aspartate transcarbamylase 10.15 242827.1 18105007 1
carbamoylphosphate synthetase 2/aspartate transcarbamylase 130.24 242827.1 18105007 13
chaperonin 10.13 61016.5 41399285 1
chaperonin 20.17 61016.5 41399285 2
chloride channel, nucleotide-sensitive, 1A 10.19 26198.9 4502891 1
chloride channel, nucleotide-sensitive, 1A 10.20 26198.9 4502891 1
complement component 3 precursor 260.28 187029.3 115298678 32
complement component 3 precursor 20.14 187029.3 115298678 2
complement component 4B preproprotein 90.26 192629.6 178557739 10
complement component 4B preproprotein 10.12 192629.6 178557739 1
CREB binding protein isoform a 30.20 265180.1 119943104 3
CREB binding protein isoform a 100.26 265180.1 119943104 11
DEAD (Asp-Glu-Ala-Asp) box polypeptide 1 20.16 82379.9 4826686 2
DEAD (Asp-Glu-Ala-Asp) box polypeptide 1 20.12 82379.9 4826686 2
DEAD (Asp-Glu-Ala-Asp) box polypeptide 4 isoform 2 10.13 75773.2 216548263 1
DEAD (Asp-Glu-Ala-Asp) box polypeptide 4 isoform 2 10.13 75773.2 216548263 1
DEAD (Asp-Glu-Ala-Asp) box polypeptide 5 20.16 69104.8 4758138 2
DEAD (Asp-Glu-Ala-Asp) box polypeptide 5 20.15 69104.8 4758138 2
dynein heavy chain domain 3 10.13 507374.4 75677365 1
dynein heavy chain domain 3 10.12 507374.4 75677365 1
E1A binding protein p300 50.16 263988.7 50345997 5
E1A binding protein p300 230.27 263988.7 50345997 29
eukaryotic translation elongation factor 1 alpha 1 40.18 50109.2 4503471 5
eukaryotic translation elongation factor 1 alpha 1 30.20 50109.2 4503471 4
eukaryotic translation elongation factor 1 gamma 20.20 50087.2 4503481 2
eukaryotic translation elongation factor 1 gamma 20.20 50087.2 4503481 2
glutamyl-prolyl tRNA synthetase 10.12 170482.3 62241042 1
glutamyl-prolyl tRNA synthetase 10.14 170482.3 62241042 1
haptoglobin isoform 2 preproprotein 70.20 38427.3 186910296 9
haptoglobin isoform 2 preproprotein 30.18 38427.3 186910296 3
heat shock 70kDa protein 1A 100.22 70009.2 194248072 11
heat shock 70kDa protein 1A 170.24 70009.2 194248072 24
heat shock 70kDa protein 1-like 10.21 70331.5 124256496 1
heat shock 70kDa protein 1-like 10.25 70331.5 124256496 1
heat shock 70kDa protein 8 isoform 2 80.23 53484.5 24234686 9
heat shock 70kDa protein 8 isoform 2 140.25 53484.5 24234686 17
heat shock 70kDa protein 9 precursor 10.17 73634.8 24234688 1
heat shock 70kDa protein 9 precursor 50.21 73634.8 24234688 5
heat shock protein 90kDa alpha (cytosolic), class A member 1 isoform 2 10.17 84606.7 154146191 1
heat shock protein 90kDa alpha (cytosolic), class A member 1 isoform 2 30.17 84606.7 154146191 3
heterogeneous nuclear ribonucleoprotein H2 30.24 49232.3 74099697 5
heterogeneous nuclear ribonucleoprotein H2 30.22 49232.3 74099697 3
heterogeneous nuclear ribonucleoprotein K isoform a 20.20 50996.4 14165439 2
heterogeneous nuclear ribonucleoprotein K isoform a 30.18 50996.4 14165439 3
heterogeneous nuclear ribonucleoprotein U isoform a 30.14 90528.0 74136883 3
heterogeneous nuclear ribonucleoprotein U isoform a 20.16 90528.0 74136883 2
hypothetical protein LOC51493 10.15 55175.0 7657015 1
hypothetical protein LOC51493 10.12 55175.0 7657015 1
influenza virus NS1A binding protein 30.18 71682.9 24475847 3
influenza virus NS1A binding protein 10.14 71682.9 24475847 1
inter-alpha (globulin) inhibitor H4 40.25 103293.2 31542984 6
inter-alpha (globulin) inhibitor H4 10.22 103293.2 31542984 1
interleukin enhancer binding factor 3 isoform e 10.12 76454.2 212549555 1
interleukin enhancer binding factor 3 isoform e 20.12 76454.2 212549555 2
LINE-1 type transposase domain containing 1 10.12 98788.5 157694505 1
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LINE-1 type transposase domain containing 1 10.12 98788.5 157694505 1
LINE-1 type transposase domain containing 1 10.12 98788.5 157694505 1
mesotrypsin isoform 1 preproprotein 10.16 32478.0 170296790 1
mesotrypsin isoform 1 preproprotein 10.15 32478.0 170296790 1
nucleolin 60.18 76568.5 55956788 6
nucleolin 40.14 76568.5 55956788 4
phosphoribosyl pyrophosphate synthetase-associated protein 2 10.17 40899.4 4506133 1
phosphoribosyl pyrophosphate synthetase-associated protein 2 10.16 40899.4 4506133 1
PREDICTED: similar to 22kDa peroxisomal membrane protein-like 10.17 41420.8 169205662 1
PREDICTED: similar to 22kDa peroxisomal membrane protein-like 10.18 41420.8 169205662 2
PREDICTED: similar to BCL2-associated transcription factor 1 isoform 1 10.17 79930.8 169218322 1
PREDICTED: similar to BCL2-associated transcription factor 1 isoform 2 10.16 100079.5 169218320 1
protein arginine methyltransferase 5 isoform a 10.22 72637.7 20070220 2
protein arginine methyltransferase 5 isoform a 10.21 72637.7 20070220 3
protein arginine methyltransferase 5 isoform b 160.27 71275.1 88900507 25
protein arginine methyltransferase 5 isoform b 100.27 71275.1 88900507 15
protein phosphatase 1B isoform 3 10.16 20740.1 29558099 1
protein phosphatase 1B isoform 3 10.17 20740.1 29558099 1
protein phosphatase 1B isoform 5 70.20 42059.5 75813620 12
protein phosphatase 1B isoform 5 50.23 42059.5 75813620 5
pyruvate kinase, muscle isoform M1 10.12 58025.1 33286422 1
pyruvate kinase, muscle isoform M1 10.15 58025.1 33286422 1
replication protein A1, 70kDa 10.14 68095.4 4506583 1
replication protein A1, 70kDa 20.17 68095.4 4506583 2
ribosomal protein L11 10.16 20239.7 15431290 1
ribosomal protein L11 10.13 20239.7 15431290 1
ribosomal protein L23a 10.12 17684.1 17105394 1
ribosomal protein L23a 10.17 17684.1 17105394 1
ribosomal protein P0 10.12 34251.8 16933546 1
ribosomal protein P0 10.12 34251.8 16933546 1
ribosomal protein S3 20.13 26671.4 15718687 2
ribosomal protein S3 20.16 26671.4 15718687 2
RIO kinase 1 isoform 1 10.14 65541.8 23510356 1
RIO kinase 1 isoform 1 20.13 65541.8 23510356 2
RIO kinase 1 isoform 2 10.18 38019.1 23510358 1
RIO kinase 1 isoform 2 10.19 38019.1 23510358 2
RNA binding motif protein 10 isoform 1 10.13 103469.3 20127479 1
RNA binding motif protein 10 isoform 1 10.12 103469.3 20127479 1
RNA binding motif protein 10 isoform 2 20.13 94312.2 23111018 2
RNA binding motif protein 10 isoform 2 10.15 94312.2 23111018 1
S100 calcium-binding protein A9 10.13 13233.5 4506773 1
S100 calcium-binding protein A9 10.15 13233.5 4506773 1
serine proteinase inhibitor, clade A, member 1 60.30 46707.1 189163542 12
serine proteinase inhibitor, clade A, member 1 50.27 46707.1 189163542 5
serine/threonine kinase 38 20.16 54155.4 6005814 2
serine/threonine kinase 38 10.12 54155.4 6005814 1
small nuclear ribonucleoprotein polypeptide D3 10.15 13907.3 4759160 1
small nuclear ribonucleoprotein polypeptide D3 10.15 13907.3 4759160 1
sodium channel, voltage-gated, type X, alpha 10.14 220481.8 110835710 2
sodium channel, voltage-gated, type X, alpha 10.12 220481.8 110835710 2
splicing factor 3b, subunit 1 isoform 1 30.16 145738.0 54112117 3
splicing factor 3b, subunit 1 isoform 1 10.12 145738.0 54112117 1
splicing factor 3b, subunit 3 50.15 135491.9 54112121 5
splicing factor 3b, subunit 3 10.15 135491.9 54112121 1
splicing factor proline/glutamine rich 10.14 76101.8 4826998 1
splicing factor proline/glutamine rich 10.15 76101.8 4826998 1
transferrin 160.26 76999.7 4557871 18
transferrin 10.14 76999.7 4557871 1
tripartite motif-containing 10 isoform 1 10.15 55001.7 157426898 1
tripartite motif-containing 10 isoform 1 10.13 55001.7 157426898 1
tubulin, alpha 1a 70.29 50103.7 17986283 7
tubulin, alpha 1a 90.29 50103.7 17986283 14
tubulin, alpha, ubiquitous 10.17 50119.6 57013276 1
tubulin, alpha, ubiquitous 20.16 50119.6 57013276 2
tubulin, beta 50.20 49639.0 29788785 7
tubulin, beta 70.20 49639.0 29788785 7
tubulin, beta 4 10.23 49553.9 21361322 1
tubulin, beta 4 20.24 49553.9 21361322 2
tubulin, beta, 4 70.23 50400.3 50592996 10
tubulin, beta, 4 120.24 50400.3 50592996 17
WD repeat domain 77 80.29 36701.1 13129110 11
WD repeat domain 77 40.31 36701.1 13129110 6
zinc finger, CCHC domain containing 11 isoform a 10.12 185134.4 57863248 1
zinc finger, CCHC domain containing 11 isoform a 10.13 185134.4 57863248 2
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Table 1. List of CITED2-interacting proteins. 
HEK293T cells were transfected with Flag/SBP-CITED2 and 
proteins in cell lysates were precipitated by anti-Flag or 
streptavidin affinity beads. Co-precipitated proteins were 
identified using LC-MS/MS. The proteins commonly precipitated 
by both affinity beads are listed.
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Table 2. Sequences of primers used in PCR and ChIP.





























Table 3. Clinical information on prostate cancer patients.
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DISCUSSION
The current treatments for prostate cancer include surgery, 
irradiation, and androgen deprivation, but none of these 
treatments are effective for metastatic castration-resistant 
prostate cancer (CRPC). Docetaxel is currently used to treat 
CRPC, because it prolongs the median survival by 3 months (37), 
and abiraterone is an emerging anti-CRPC drug capable of 
increasing the survival by 4 months (38). Unfortunately, the 
anticancer effects of these drugs are very limited because of the 
development of drug resistance (39, 40). In this study, CITED2 
was found to be uniquely overexpressed in prostate cancer cells, 
in which it promoted metastasis by activating the nucleolin-AKT 
signaling pathway. I therefore propose that CITED2 may be a 
potential target for treating metastatic prostate cancer. 
ERG is an important factor that contributes to prostate 
cancer progression (4, 5). It is not expressed in normal prostate 
epithelium but is markedly amplified in prostate cancer because 
of its gene fusion to the androgen-driven promoter TMPRSS2 
(41). Other ETS gene family members, such as ETV1, ETV4, 
ETV5, and FLI1, can also fuse to TMPRSS2, but these fusion 
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events display much lower frequencies compared with ERG (42-
44). The significance of ERG gene fusion was demonstrated by 
its correlation with the clinical phase of patients. ERG expression 
was positively correlated with the Gleason score in prostate 
cancer tissues, and it was associated with prostate cancer 
metastasis and poor patient prognoses (45). Many follow-up 
studies have been conducted to understand how ERG promotes 
prostate cancer. For example, one study reported that ERG 
reorganizes actin filaments by activating vimentin and 
upregulating matrix metalloproteinases, leading to cell invasion 
(46). ERG was also reported to facilitate cell movement by 
inducing the EMT (47). However, the downstream signaling 
pathway responsible for ERG-driven metastasis remains unclear. 
I identified ERG as a transcription factor regulating expression 
of the CITED2 gene, which is specifically overexpressed in 
prostate cancer, and further clarified the ERG-CITED2 axis as 
the downstream pathway involved in prostate cancer. 
Because nucleolin exists in a complex with PRMT5 and p300, 
I tested the possibility that nucleolin is post-translationally co-
modified by PRMT5 and p300. Although arginine methylation 
does not significantly affect the overall charge of nucleolin, steric 
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hindrance or hydrogen bonds around arginine could be altered. 
Thus, methylation can modify intermolecular interactions (48-
50). In proteins containing the RNA-binding RGG domain, 
alterations of protein–RNA interactions by methylation have been 
reported previously (51). Because nucleolin is also an RNA-
binding protein with a RGG motif (52), I tested the possibility 
that nucleolin binding to AKT mRNA is regulated by the PRMT5-
mediated arginine dimethylation of nucleolin. Methylation 
enhanced the interaction between nucleolin and AKT mRNA, 
thereby facilitating de novo synthesis of AKT translationally. 
However, lysine acetylation of nucleolin has not been 
investigated comprehensively. A previous study reported that 
p300-mediated lysine acetylation stabilized nucleolin (53). 
However, I observed no change in the level of nucleolin after 
overexpressing or knocking-down p300. According to another 
study, acetylation may influence the binding between nucleolin
and nucleic acids. Lysine acetylation is essential for STAT3 or 
p53 binding to DNA (54, 55). In a similar manner, I speculate 
that nucleolin acetylation by P300 can affect mRNA polysome 
formation. This possibility needs to be confirmed by additional 
studies. 
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Notably, I found that the nucleolin complex was present 
mainly in the nucleus, but nucleolin was bound to AKT mRNA in 
the cytoplasm. The difference in the location of nucleolin
suggests that nucleolin is post-translationally modified in the 
nucleus and then transported to the cytoplasm. Because the 
entire nucleolin complex was too large to pass through the 
nuclear membrane, it is reasonable to assume that the modified 
nucleolin is released from the complex and then translocated to 
the cytoplasm. Consistent with these possibilities, a study 
demonstrated translocation of nucleolin from the nucleus to the 
cytoplasm and the plasma membrane after phosphorylation (56). 
However, no study has reported the translocation of nucleolin
after acetylation or methylation, which suggests a mechanism 
underlying nucleolin translocation. 
Although CITED2 has no special functional domain, it can 
participate in important biological processes as a scaffolding 
protein. CITED2 is comprised of three CR(1-3) and one SRJ 
domains (57, 58). Because each domain provides a docking site 
for protein interactions, CITED2 with multiple domains may act 
as a central scaffold recruiting different proteins. For example, 
CR2 interacts with transcription factors such as TFAP2, HNF4a, 
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PPARa/r, and Smad 2/3 and enhances gene expression by 
recruiting CBP/p300 (6, 10, 59, 60). CR1 interacts with the 
GCN5 acetyltransferase, thereby inhibiting the GCN5-mediated 
acetylation of PGC-1a (61). CR3 binds to the homeobox protein 
LHx2 and increases expression of glycoprotein hormone a-
subunit (62). Because I am intrigued by the numerous functions 
of CITED2, which depend on its binding molecule, I investigated 
its potential role in tumorigenesis. Previous studies have 
reported that CITED2 increases cancer progression. It has been 
reported that CITED2 promotes MYC-mediated transactivation 
of the E2F3 gene by recruiting p300 to stimulate lung cancer 
progression (16). However, little is known about the role of 
CITED2 in cancer metastasis. I thus conducted a screening in 
patients to identify the cancer type most affected by CITED2 
expression and found that CITED2 was most elevated in 
metastatic prostate cancer. However, considering that a kind of 
cytokine storm occurs in tumor microenvironment, CITED2 could 
be differentially expressed in primary and metastatic tumors 
because they grow with distinct stromal cells. Indeed, various 
growth factors and cytokines have been reported to increase 
CITED2 expression(8). Therefore, I cannot rule out the 
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possibility that CITED2 is overexpressed in metastatic tumor 
milieu. Nonetheless, our cellular and animal experiments support 
our notion that ERG-induced CITED2 promotes prostate cancer 
metastasis. According to this scenario, CITED2 could be a 
potential target to prevent prostate cancer metastasis. Since the 
complete inhibition of CITED2 has been reported to induce acute 
bone marrow failure (14), the anti-CITED2 strategy should be 
carefully optimized before clinical application.
Because AKT is involved in important oncogenic pathways, 
most studies have emphasized its role in survival and the cell 
cycle. AKT activates the mTOR pathway, which increases cyclin 
D1 translation to promote cell cycle progression (63), and 
stimulates CREB activity to induce survival genes such as Bcl-2
(64). Many recent studies have also characterized the roles of
AKT in EMT and cell migration. AKT not only increases SNAIL 
expression by activating NF-kB (36), but also stabilizes the 
SNAIL protein by inactivating GSK-3b (65). Moreover, AKT 
enhances transcription of the SNAIL and SLUG genes by 
phosphorylating b-catenin (66). According to past studies, the 
AKT pathway is aberrantly activated in cancers because of AKT
gene amplification and the PTEN gene deletion (67). Our study 
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suggests a mechanism involving AKT activation in prostate 
cancer. The CITED2 stimulation of AKT translation strengthens 
AKT signaling to promote EMT and eventually cancer metastasis. 
In this study, I identified a pathway related to metastasis, 
involving ERG, CITED2, nucleolin, and AKT pathway, in prostate 
cancer. This metastasis-promoting mechanism may be 
particularly important in prostate cancer overexpressing ERG 
due to gene fusion events involving ERG. I also identified CITED2 
and nucleolin as target molecules for preventing prostate cancer 
metastasis in an orthotopic xenograft animal model. Overall, this 
study provides a basis for future concept studies to develop the 
next generation of prostate cancer treatments. 
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전립선암 전이를 치료하기 위해 그 동안 호르몬 치료와 화학적
요법을 개발하여 많은 시도가 이루어져 왔다. 하지만 효과적인 치료
방법은 개발되지 못했고 전립선암 전이 조절 기작은 완전히 밝혀지
지 않았다. 본 연구는 CITED2가 전립선암 조직에서 특이적으로 과
발현 되어 있는 것을 주목하였고 이러한 발현량은 전립선암 환자의
예후와 관련이 있었다. ETS 관련 유전자 (ERG)는 전립선암 환자의
약 30% 이상 유전자 융합이 이루어져 있으며 그로 인해 ERG는 전
립선암에서 과발현 되었다. 본 논문을 통해 ERG는 CITED2의 전사
인자로 작용하며 이를 기전으로 CITED2가 전립선암에서 증가된 원
인을 제시하였다. ERG로 인해 과활성화된 CITED2는 PRMT5와
P300을 뉴클레오린으로 안내하여 각각 이중 메틸화와 아세틸화를
시킴으로써 뉴클레오린을 활성화시킨다. 전립선암은 PTEN 유전자
의 소실로 인해 AKT가 활성화되어 있다. 하지만 앞선 기전 말고는
AKT 활성화에 대해 완전히 밝혀지지 않았다. 놀랍게도, 활성화된
뉴클레오린은 핵에서 세포질로 이동하게 되고 세포질에서 AKT 
mRNA의 번역을 촉진시킨다. 이를 통해 AKT의 합성이 증가되었고
증가된 AKT로 인해 활성화 형태인 p-AKT의 양 또한 증가된다.
본 논문은 전립선암 조직 중 전이 조직에서 CITED2의 발현이 높은
것에 착안하여 전립선암세포의 전이에 CITED2가 관여할 것이라 가
설을 세웠다. 암세포에 CITED2를 과발현하게 되면 암세포에서 강
력한 상피-중간엽 전환이 일어났으며 이러한 효과는 뉴클레오린을
억제 했을 때 상쇄되었다. 더욱이 이러한 현상이 전립선암세포주를
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이식한 설치류 실험에서도 CITED2 과발현 세포주에서 암 전이가
높았으며 CITED2를 억제할 시 전이가 낮아졌고 CITED2의 하위인
자인 뉴클레오린을 억제하게 되면 CITED2가 높아도 전이가 촉진되
지 않음을 증명하였다.
이를 통해 CITED2-뉴클레오린 기전이 AKT를 활성화 시킴으로
써 전립선암세포의 상피-중간엽 전환을 촉진시켰고 이를 기반으로
전립선암 전이가 촉진되는 것을 세포수준부터 설치류 실험과 나아
가 환자 조직에서 CITED2가 전립선암 전이를 촉진시킴을 밝혔다.
CITED2는 전립선암 전이 치료에 있어서 새로운 중요한 표적이 될
수 있을 것이라 기대한다.
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